Harrow Inc. experienced a brief 20% stock drop in October but quickly recovered, showing resilience despite recent revenue channel underperformance. HROW's new branded pharmaceutical products, ...

Harrow, Inc. continues to execute on its branded ophthalmic portfolio, with Vevye and Iheezo outperforming expectations. Read ...

Harrow (NASDAQ:HROW) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the fourth quarter and ...

We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will ...

NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced its first major market access wins in the 2025 Medicare Part D ...

Harrow HROW will release its quarterly earnings report on Monday, 2025-08-11. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Harrow to report an earnings per ...

Shares of Harrow fell after earnings and revenue missed Wall Street's expectations in the latest quarter due to underperformance for its Triesence product. The stock declined 7.7% to $31.50 in ...

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 28, 2025 Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it ...